黑色素瘤治疗药物的研究进展  

Analysis on current situation and development trend of melanoma drugs

作　　者：田红[1] 肖桂芝[1] 田苗[1] 刘永贵[1] 贺星[1] 陈常青[1] 

机构地区：[1]天津药物研究院医药信息中心,天津300193

出　　处：《现代药物与临床》2015年第7期890-896,共7页Drugs & Clinic

摘　　要：黑色素瘤是临床上常见的皮肤恶性肿瘤,且发病率呈逐年增加的趋势。该病恶性程度高,易发生转移。全球新批准并上市的治疗黑色素瘤的治疗药物有威罗菲尼、达拉菲尼、曲美替尼、易普利姆玛、nivolumab以及pembrolizumab,处于研发后期的黑色素瘤治疗药物有cobimetinib、binimetinib、talimogene laherparepvec、贝伐单抗、seviprotimut-L、NGc GM3/VSSP以及c-Kit抑制剂甲磺酸伊马替尼等。对近年来上市和处于研发后期的黑色素瘤的治疗药物进行了详细介绍,同时对其未来发展方向进行了展望,以期为黑色素瘤治疗药物的研发指明方向,给黑色素瘤患者带来希望。Melanoma is the clinical common skin malignant tumor, and its incidence rate has increased year by year. The malignant degree of melanoma is high, and easy to shift. Melanoma drugs approved for sale include zelboraf, dabrafenib, trametinib, ipilimumab, nivolumab, and pembrolizumab. Melanoma drugs under development include cobimetinib, binimetinib, talimogene laherparepvec, bevacizumab, seviprotimut-L, NGc GM3/VSSP, and c-Kit inhibitor imatinib mesylate. Melanoma drugs（launched and R D） are introduced, and the future development direction of melanoma drugs is prospected in this paper, in order to provide a basis for melanoma drugs, and give hope for melanoma patients.

关 键 词：治疗药物 黑色素瘤 曲美替尼 贝伐单抗 甲磺酸伊马替尼 

分 类 号：R979.1[医药卫生—药品]